New trial tests chemo combo to stop rare adrenal Cancer's return

NCT ID NCT03583710

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This Phase 3 trial tests whether adding chemotherapy (cisplatin and etoposide) to the standard drug mitotane after surgery works better than mitotane alone for patients with adrenocortical carcinoma at high risk of recurrence. The study plans to enroll 240 adults with stage I-III disease who had their tumor removed. The main goal is to see which approach delays or prevents the cancer from coming back.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mitotane, cisplatin, etoposide
What this could lead to: If successful, this could show that adding chemotherapy to mitotane after surgery reduces the chance of adrenocortical carcinoma coming back in high-risk patients.
What could go wrong: This is an early-stage Phase 3 trial with only 240 participants, so results may not apply to all patients. Chemotherapy adds significant side effects, and it's unclear if the combination is better than mitotane alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adrenal cortex carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENSAT STAGE I ADRENAL CORTEX CARCINOMA ENSAT STAGE II ADRENAL CORTEX CARCINOMA ENSAT STAGE III ADRENAL CORTEX CARCINOMA

Contacts and locations

Locations

Akademiska Sjukhuset
RECRUITING

Uppsala, Sweden
CHU Angers, Hôpital Larrey
RECRUITING

Angers, 49933, France
CHU Besançon, Hôpital Jean Minjoz
RECRUITING

Besançon, 25000, France
CHU Bordeaux - Hôpital Haut Lévèque
RECRUITING

Pessac, 33600, France
CHU Brest, Hôpital La Cavale Blanche
ACTIVE_NOT_RECRUITING

Brest, 29200, France
CHU Nantes, Hôpital René et Guillaume Laënnec
ACTIVE_NOT_RECRUITING

Nantes, 44093, France
CHU Nantes, Hôpital René et Guillaume Laënnec
RECRUITING

Nantes, 44093, France
CHU Poitiers
RECRUITING

Poitiers, 86000, France
CHU Reims
RECRUITING

Reims, 51092, France
CHU Toulouse, Hôpital Larrey
RECRUITING

Toulouse, 31059, France
CHU Toulouse, Hôpital Rangueil
ACTIVE_NOT_RECRUITING

Toulouse, 31400, France
Centre Georges François Leclerc
RECRUITING

Dijon, 25000, France
Gustave Roussy
RECRUITING

Villejuif, 94805, France
HCL Hôpital Louis Pradel
NOT_YET_RECRUITING

Lyon, 69877, France
HUS, Hôpital Hautepierre
NOT_YET_RECRUITING

Strasbourg, 67000, France
Hôpital COCHIN
ACTIVE_NOT_RECRUITING

Paris, 75014, France
Hôpital Cochin
RECRUITING

Paris, 75014, France
Hôpital Cochin, AP-HP
RECRUITING

Paris, 75014, France
Hôpital Cochin, AP-HP
ACTIVE_NOT_RECRUITING

Paris, 75014, France
Institut de Cancérologie de l'Ouest (ICO)
ACTIVE_NOT_RECRUITING

Angers, 49055, France
Karolinska University Hospital
RECRUITING

Stockholm, Sweden
LMU Klinikum München
RECRUITING

Munich, 80336, Germany
Lyon HCL
RECRUITING

Lyon, 69002, France
M D Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Maria Sklodowska-Curie National Research Institute of Oncology
ACTIVE_NOT_RECRUITING

Gliwice, 44-102, Poland
Marseille Hôpital Nord
RECRUITING

Marseille, 13015, France
Marseille Hôpital de la Conception
RECRUITING

Marseille, France
Sahlgrenska University Hospital
RECRUITING

Gothenburg, Sweden
Siteman Cancer Center at Washington University
ACTIVE_NOT_RECRUITING

St Louis, Missouri, 63110, United States
Skånes Universitetssjukhus
RECRUITING

Lund, Sweden
Strasbourg HUS Hautepierre
ACTIVE_NOT_RECRUITING

Strasbourg, 67000, France
University of Michigan Comprehensive Cancer Center
RECRUITING

Ann Arbor, Michigan, 48109, United States
Universitätsklinikum Würzburg
RECRUITING

Würzburg, 97080, Germany